Stuart Kupfer - Concepedia

Author

Stuart Kupfer

Takeda (United States)ORCID

Also Known As

J K Freedman, S KUPFER, S Kupfer, S. Kupfer, STUART KUPFER, Stuart F Kupfer, Stuart Kupfer

156

Publications

8.8K

Citations

H-Index

Concepts

All Affiliations

Takeda (United States)Brigham and Women's Hospital Cytokinetics (United States)Harvard University University of Glasgow

About

Stuart Kupfer is an author at Takeda (United States) specializing in medicine, cardiovascular disease, and diabetes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	16	1.7K
2	Diabetes	8	8	1.2K
3	Public Health	7	7	975
4	Emergency Medicine	3	3	61
5	Epidemiology	2	2	135

Stuart Kupfer

Publications

8.5K

Citations

H-Index

Page 1

	Year	Citations
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes William B. White, Christopher P. Cannon, Simon Heller, New England Journal of Medicine	2013	2.5K
Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Steven E. Nissen, Stephen J. Nicholls, Kathy Wolski, JAMA	2008	846
Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? Franz H. Messerli, Giuseppe Mancia, C Conti, Annals of Internal Medicine	2006	773
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Faı̈ez Zannad, Christopher P. Cannon, William C. Cushman, The Lancet Diabetes ManagementHeart FailureAlogliptin Versus PlaceboCardiovascular DiseaseHealth Policy	2015	748
Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke Robert Wilcox, Marie‐Germaine Bousser, D. J. Betteridge, Stroke	2007	473
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Martin S. Maron, Ahmad Masri, Michael E. Nassif, New England Journal of Medicine	2024	230
Clinical Outcome Endpoints in Heart Failure Trials: A European Society of Cardiology Heart Failure Association Consensus Document Faı̈ez Zannad, Ángeles García, Stefan D. Anker, European Journal of Heart Failure	2013	229
Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension William B. White, Michael A. Weber, Domenic Sica, Hypertension ThrombosisHypertensionAzilsartan MedoxomilStages 1Cardiovascular Disease	2011	213
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy Martin S. Maron, Ahmad Masri, Lubna Choudhury, Journal of the American College of Cardiology	2023	178
The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure George L. Bakris, Domenic Sica, Michael A. Weber, Journal of Clinical Hypertension	2011	141

Page 1